Article

Compliance by Design and Compliance Master Plans

Video with Paul Pluta

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Subscribe Now!
Related Videos
Behind the Headlines, Episode 23: Patent Cliff Deals, Tariff Pressures, and the In Vivo Cell Therapy Bet
Related Content
Human eye close-up in black and white. Extended pupil | Image Credit: © Annashou - stock.adobe.com
August 27th 2025

VeonGen’s Stargardt Disease Gene Therapy Gets FDA RMAT Status

Patrick Lavery
PRAGUE, CZECHIA - NOVEMBER 1, 2019: Astellas logo in front of their main office for Prague. Astellas Pharma is a Japanese Pharmaceutical company spread worldwide | Image Credit: © Jerome - stock.adobe.com
August 27th 2025

Astellas and Pfizer Bladder Cancer Therapy Recommended by UK’s NICE

Patrick Lavery
The front of the REGENXBIO facility in Rockville, Montgomery County, Maryland. REGENXBIO is a biotechnology company researching Adeno-Associate Virus (AAV) gene therapy | Image Credit: © MJ Kerr - stock.adobe.com
August 27th 2025

FDA Extends Review Period for REGENXBIO Hunter Syndrome Treatment

Patrick Lavery
Lung cancer, 3D illustration and photo under microscope. Histopathology light micrograph of small cell lung cancer | Image Credit: © Dr_Microbe - © Dr_Microbe - stock.adobe.com
August 27th 2025

Merck and Daiichi Sankyo’s I-DXd Earns FDA Breakthrough Therapy Status in Small Cell Lung Cancer

Feliza Mirasol
Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com
August 27th 2025

FDA Grants Breakthrough Therapy Designation to Bispecific ADC for EGFR-Mutant Lung Cancer

Feliza Mirasol
Human papillomavirus infection. Virus. HPV is the most common sexually transmitted infection globally. HPV infection is caused by human papillomavirus, a DNA virus from the papillomavirus family, 3d | Image Credit: © Naeblys - stock.adobe.com
August 27th 2025

FDA Approves Precigen’s Immunotherapy to Treat Recurrent Respiratory Papillomatosis

Patrick Lavery
© 2025 MJH Life Sciences

All rights reserved.